Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Broad, Gyros, and More

Premium

Louis Gerstner has been elected chairman of the Broad Institute's board of directors, succeeding outgoing chair Diana Chapman Walsh, who will continue to serve on the board as vice chair.

Gerstner was elected to the Broad's board in 2010. He was CEO and chairman of the board of IBM from 1993 to 2002 and has also served as chairman of the Carlyle Group and CEO of RJR Nabisco.


Gyros said this week that it has appointed Henrik Bjorkman chief technology officer and vice president of technical affairs.

Previously, Bjorkman was director of MicroCal R&D at GE Healthcare Life Sciences.


Enzo Biochem's shareholders have re-elected Gregory Bortz and Dov Perlysky to serve on the company's board of directors for three-year terms.

Bortz is founder and managing partner of Creo Capital Partners and he previously was senior VP of the investment banking division of Lehman Brothers. Perlysky has been a managing member of the private investment firm Nesher and a director of the mutual fund Engex, and he has served on the board of directors at Pharma-Bio Serv and Highlands Bancorp.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.